Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker UPTD, is a clinical-stage biopharmaceutical company that completed its business combination with a blank-check acquisition vehicle focused on the healthcare and life sciences sector. The company filed a Form 10-Q with the Securities and Exchange Commission on November 10, 2021, under accession number 0001410578-21-000091, reflecting its reporting obligations as a post-combination public entity. Estrella's pipeline targets immunological and inflammatory conditions, placing it within the biopharma sub-segment of SPAC-sponsored healthcare deals that were active during the 2020–2021 vintage. For complete filing history, sponsor details, and deal-level analytics on UPTD and hundreds of comparable transactions, sign up for full data access at SpacDesk.